Noble Capital Markets

 

Investment Banking

NOBLE Capital Markets's investment banking team has a singular focus: to exceed our client's expectations by providing the appropriate advice and execution necessary for efficient capital raising, mergers & acquisitions advisory and capital markets support. We leverage our fundamental sector research expertise in healthcare, natural resources, transportation & logistics, technology, media and telecom, along with our firm's three-decade history of capital markets acumen, in the creation of a customized solution for our clients.

Our investment banking team, together with our well-recognized equity research analysts and the equity capital markets group, provide our clients with fundamental capital markets advisory and support - prior, during and most importantly, after a transaction.

IB Services

NOBLE’s investment banking team works closely with the management and Board of our corporate clients to fully understand operational and financial objectives. With this knowledge our banking team will develop an efficient and effective advisory program which offers a variety of services including:

  • Mergers & Acquisitions (Buy and Sell-Side)
  • Restructuring & Recapitalizations
  • Sale or Divestitures
  • Valuations Services; Purchase Price Allocation – Goodwill Impairment – FV Measurement
  • Fairness Opinions

NOBLE’s investment banking team can achieve transactional success for our clients by tapping into our resident expertise in our research verticals, and through our long-standing relationships with leading institutional investors. NOBLE Capital Markets is routinely involved in the following Corporate Finance transactions:

  • Initial Public Offerings (IPOs)
  • Alternative Public Offerings (APOs)
  • Follow-on Offerings
  • Private Placement in Public Companies (PIPE's)
  • Private Placements in Private Companies
  • At The Market Transactions (ATMs)

Merchant Banking

Our Principal Investment focus is primarily on private and small-cap public ($10mill to $50mill market caps) companies in industries within NOBLE's research verticals. Investments are made directly by NOBLE and its affiliates and may also involve syndicate participants. We work to identify those companies with game-changing or superior products and technologies that have management teams with proven track-records of success. Noble structures investments to meet a company's capital needs whether its growth capital, liquidity or debt repayment. Capital commitment ranges from $200k to $2million principal and $2million above with syndicate.

The scope of our Merchant Banking activities includes:

  • Targeting domestic companies within our areas of focus and expertise
  • Analyzing a company's opportunities and assessing its risks within their respective industry
  • Structuring, negotiating and executing the transaction
  • Work in assessing the appropriate time and manner in which to harvest the investment

Post Transaction Support:
NOBLE's Merchant Banking Team works continuously with our portfolio companies to assist the management team and Board of Directors to create value and grow their businesses to facilitate long-term shareholder value. Through our extensive sector research coverage, institutional investor non-deal road shows, equity conferences and market making, we blend a powerful mix of capital markets acumen to procure success.

Transactions

NOBLE's Investment banking team has, on average, more than 25 years' experience in the industry. Transactions drive our business. Building a solid foundation of mutual respect and trust with our customers drives transactions. Here is a selection of some of the companies we've helped over the years.

Investment Banking Team

Nathan Cali

Nathan Cali

Managing Partner

Department:
Investment Banking
Healthcare

E: ncali@noblelsp.com
T: (561) 994-5723
VCard: Nathan Cali

Mr. Cali is a Managing Partner at Noble Capital Markets, Inc. Nathan Cali has more than 19 years of combined healthcare, biotechnology, and pharmaceutical experience. He has led the Healthcare Investment Banking franchise at Noble since 2017 and, was previously a sell-side analyst for 9 years with expertise and publications cover many areas of biotechnology, specialty pharmaceuticals (branded and generics), and medical devices. Mr. Cali is a Board Member of Precise Bio, a tissue engineering, biomaterials, cell technologies, including, cardiology, orthopedics, and dermatology. He was previously a Board observer of Eledon Pharmaceuticals (ELDN:NASDAQ, f.k.n.a. Anelixis Therapeutics, Inc.), a phase II biotechnology company pursuing transplant, autoimmune, and neurology treatments. He is currently a Committee Member at the Moffitt Cancer Center for Commercialization. Mr. Cali has been quoted in most business journals including Reuters, BioMed Reports and the Washington Business Journal for his work as a sells-side analyst. Mr. Cali started his career in healthcare at Andrx Corporation, a biotechnology and specialty pharmaceuticals company known for its expertise in the development of controlled-release drugs. Mr. Cali was a corporate manager dealing in finance, state taxation, corporate governance, patents, drug distribution and business development for the biotechnology firm. Andrx was purchased by Watson Pharmaceuticals in 2006 for $2.0 billion in cash. Prior to joining NOBLE, Mr. Cali gained investment experience as a portfolio account analyst/manager at Franklin Templeton Investments. Mr. Cali holds a B.S. in Finance from The Florida State University and an M.B.A. in Finance from Nova Southeastern University. Nathan also currently holds series 7, 79, 86, and 87 FINRA designations.

Nathan Cali, Managing Partner

Francisco Penafiel

Francisco Penafiel

Managing Director, Operations and Investment Banking

Department:
Investment Banking

E: fpenafiel@noblecapitalmarkets.com
T: (561) 994-5740
VCard: Francisco Penafiel

Francisco Penafiel joined NOBLE Capital Markets in 2002 after earning his Master of Science in Economics, with concentrations in Finance and International Economics from Florida Atlantic University. He obtained his undergraduate degree from Escuela Superior Politecnica in Ecuador, where he double-majored in Statistics and Computing Science. Prior to joining the investment banking department at Noble in 2011, Francisco was part of NOBLE's research department, working as a supervisory analyst and equity research analyst covering the enterprise/infrastructure software and business services industries. Other responsibilities included portfolio managing, computer modeling analysis and statistical review. He is also a member of the Company's Investment Policy Committee. Francisco holds various FINRA licenses and is a candidate in the CFA program.

Francisco Penafiel, Managing Director, Operations and Investment Banking